US 12,312,413 B2
Antibodies and methods for making and using the same
Yuefeng Lu, Newbury Park, CA (US); Kurt Shanebeck, Camarillo, CA (US); Lu Li, Camarillo, CA (US); Lei Liu, Thousand Oaks, CA (US); Shiwen Zhang, Camarillo, CA (US); Lan Yang, Camarillo, CA (US); and Jian-Feng Lu, Oak Park, CA (US)
Assigned to AskGene Pharma Inc.; and Jiangsu AoSaiKang Ph, Nanjing (CN)
Filed by AskGene Pharma Inc., Camarillo, CA (US); and Jiangsu AoSaiKang Pharmaceutical Co., Ltd., Nanjing (CN)
Filed on Nov. 21, 2022, as Appl. No. 17/991,775.
Application 17/991,775 is a division of application No. 16/516,223, filed on Jul. 18, 2019, granted, now 11,505,618.
Claims priority of provisional application 62/792,798, filed on Jan. 15, 2019.
Claims priority of provisional application 62/700,174, filed on Jul. 18, 2018.
Prior Publication US 2023/0303714 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/765 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/3046 (2013.01) [A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 39/39558 (2013.01); A61K 47/6863 (2017.08); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/765 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)] 14 Claims
 
1. A method of treating a CLDN18.2 expressing cancer in a subject, the method comprising administering a therapeutic amount of a humanized antibody to the subject,
wherein the humanized antibody comprises a heavy chain variable domain selected from SEQ ID NO: 263, 264 and 265 and a light chain variable domain selected from SEQ ID NO: 266, 267, 268 and 269.